HPV Vaccine Therapy in Interrupting Progression in Patients With High-Grade Vulvar or Anal Lesions

This phase IV trial studies how well human papillomavirus (HPV) vaccine therapy works in
interrupting progression in patients with high-grade vulvar or anal lesions. Vaccines made
from HPV peptides or antigens may help the body build an effective immune response to kill
tumor cells and decrease the chance of vulvar or anal lesions to progress or come back.

Intervention

Laboratory Biomarker Analysis, Placebo Administration, Questionnaire Administration, Recombinant Human Papillomavirus Nonavalent Vaccine

Condition

High Grade Anal Canal Intraepithelial Neoplasia, High Grade Vulvar Squamous Intraepithelial Lesion

Investigators

Anna Wald

See list of participating sites